N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)cyclohexanecarboxamide hydrochloride | 146714-97-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)cyclohexanecarboxamide hydrochloride
• 英文别名: N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide;hydrochloride
• CAS: 146714-97-8
• 化学式: C25H35ClN4O2
• 分子量: 459.0
• InChiKey: HORQTONVLZMNKK-UHFFFAOYSA-N

物化性质

• 熔点：
  176-178°C
• 溶解度：
  二氯甲烷（微溶，加热）、甲醇（微溶，加热）、水（微溶，加热）

计算性质

• 辛醇/水分配系数(LogP)：
  4.25
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  48.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
  申请人：Leonardi Amedeo

  公开号：US20050165025A1

  公开（公告）日：2005-07-28

  Described is the novel use of combinations of molecules endowed with antagonistic activity toward the serotonin 5-HT 1A or 5-HT 1B receptor, and of molecules simultaneously endowed with antagonistic activity at both said receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates, prodrugs, and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract. Also described are the pharmaceutical compositions containing them. There is also provided a method of therapeutic treatment of urinary disorders in a mammal, including man, comprising administering to said mammal, including man, in need of such treatment, a therapeutically effective amount of a composition according to the invention.

  描述了具有拮抗血清素 5-HT 1A 或 5-HT 1B 受体具有拮抗活性的分子组合，以及同时对上述两种受体具有拮抗活性的分子组合。这些化合物及其对映体、非对映异构体、N-氧化物、多晶型物、溶解物、原药和药学上可接受的盐可用于治疗下尿路神经肌肉功能障碍患者。还描述了含有它们的药物组合物。还提供了一种治疗哺乳动物（包括人）泌尿系统疾病的方法，包括给需要这种治疗的哺乳动物（包括人）施用治疗有效量的根据本发明的组合物。
• COMBINATION THERAPY WITH 5-HT sb 1A /sb AND 5-HT sb 1B /sb RECEPTOR ANTAGONISTS
  申请人：Recordati Ireland Limited

  公开号：EP1706147A2

  公开（公告）日：2006-10-04
• [EN] COMBINATION THERAPY WITH 5-HT1A AND 5-HT1B RECEPTOR ANTAGONISTS<br/>[FR] POLYTHERAPIE AU MOYEN D'ANTAGONISTES DES RECEPTEURS 5-HT1A ET 5-HT1B
  申请人：RECORDATI IRELAND LTD

  公开号：WO2005070460A2

  公开（公告）日：2005-08-04

  A compound having 5-HT1A antagonist activity is useful for the preparation of a medicament for the treatment of neuromuscular dysfunction of the lower urinary tract in combination with the prior, concurrent or post-administration of a compound having 5-HT1B antagonist activity. Alternatively a single compound having both 5­HT1A and 5-HT1B antagonist activity is useful for the preparation of a medicament for the treatment of neuromuscular dysfunction of the lower urinary tract.